Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.46 |
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | CA7 | P43166 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6873803 | 0.84 | HPGD (0.43) | SMN1; SMN2ALDH1A1CYP1A2HPGDLMNA | |
| SCHEMBL22727456 | 0.81 | TARBP2 (0.44) | ALDH1A1CYP1A2HPGDKDM4ETARBP2 | |
| SCHEMBL26921830 | 0.81 | HTT (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL16571753 | 0.79 | HTT (0.48) | ALDH1A1HPGDLMNATARBP2HTT | |
| SCHEMBL30080002 | 0.79 | KDM4E (0.41) | ALDH1A1CYP1A2HPGDLMNAKDM4E | |
| SCHEMBL23990453 | 0.79 | CYP1A2 (0.42) | NPC1ALDH1A1CYP1A2NPSR1HPGD | |
| SCHEMBL7948540 | 0.79 | GAA (0.42) | NPC1ALDH1A1CYP1A2HPGDKDM4E | |
| SCHEMBL5801249 | 0.78 | LMNA (0.44) | NPC1SMN1; SMN2ALDH1A1CYP1A2NPSR1 | |
| SCHEMBL30281292 | 0.78 | HSP90AA1 (0.39) | SMN1; SMN2ALDH1A1CYP1A2HPGDKDM4E | |
| SCHEMBL30487833 | 0.78 | TARBP2 (0.40) | SMN1; SMN2ALDH1A1CYP1A2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| EP-4143195-B1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| US-20250136556-A1 | NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF | ALLIANTHERA BOSTON INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| CN-118748992-A | Novel modulators of aryl hydrocarbon receptors and methods of use thereof | 元启(苏州)生物制药有限公司 | 2024-10-08 | — | — | CN | disclosed |
| EP-4430028-A2 | NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) | 2024-09-18 | — | — | EP | disclosed |
| WO-2024153155-A1 | DOUBLE-HETEROCYCLIC WRN INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都微芯药业有限公司 | 2024-07-25 | — | — | WO | disclosed |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-02 | — | — | US | disclosed |
| US-20170044146-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | US | disclosed |
| WO-2017027310-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | WO | disclosed |
| US-20170044148-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | US | disclosed |
| WO-2017027312-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | WO | disclosed |
| US-20160237059-A1 | HETEROCYCLIC SUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-18 | — | — | US | disclosed |
| EP-3046911-A1 | HETEROCYCLIC SUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015036560-A1 | HETEROCYCLIC SUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-03-19 | — | — | WO | disclosed |
| US-5616579-A | ADMINISTERING TO MAMMALS TO PREVENT GASTRIC ULCER | SANKYO COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | disclosed |
| EP-0562833-B1 | Anti-ulcer pyridyloxy derivatives, their preparation and uses | SANKYO CO (JP) | 1996-05-08 | — | — | EP | disclosed |
| EP-0562833-A1 | Anti-ulcer pyridyloxy derivatives, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044148-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR52 | CA12 4386/4885CA1 4675/4885CA2 1981/4885 |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | CA12 4365/4885CA1 4571/4885CA2 3989/4885 |
| US-20250136556-A1 | NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF | AHR, ARNT, NR1H2 | CA12 4645/4885CA1 4842/4885CA2 4755/4885 |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | CA12 4843/4885CA1 4864/4885CA2 4119/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | CA12 4843/4885CA1 4863/4885CA2 4112/4885 |
| US-20170044146-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR52 | CA12 4682/4885CA1 4804/4885CA2 2600/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | CA12 4843/4885CA1 4864/4885CA2 4119/4885 |
| US-20160237059-A1 | HETEROCYCLIC SUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE | REN, GLS, FIBP | CA12 4857/4885CA1 4874/4885CA2 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.